NASDAQ
No price data available for this timeframe.
Eye-opening wealth data… a replay of this morning's "American Dream 2.0" Summit… where the government might point its investment firehose next… Eric Fry says where to invest beyond "AI"...
NEW YORK and SOUTH SAN FRANCISCO, Calif., Dec. 04, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) and Denali Therapeutics, Inc. (Nasdaq: DNLI) today announced a $275 million synthetic roya...
SOUTH SAN FRANCISCO, Calif. and NEW YORK, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) and Royalty Pharma plc (Nasdaq: RPRX) today announced a $275 million synthetic royal...
Royalty Pharma plc (RPRX) Presents at Evercore 8th Annual Healthcare Conference Transcript...
Royalty Pharma plc (RPRX) Presents at Citi Annual Global Healthcare Conference 2025 Transcript...
Creative Planning raised its stake in Royalty Pharma PLC (NASDAQ: RPRX) by 22.7% in the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). Th...
NEW YORK, Nov. 26, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in the following upcoming investor conferences during the month of December:...
Envestnet Asset Management Inc. trimmed its stake in Royalty Pharma PLC (NASDAQ: RPRX) by 6.0% during the second quarter, according to its most recent disclosure with the SEC. The fund owned 97,612 sh...
Royalty Pharma is reiterated as a Buy, supported by strong Q3 results, raised guidance, and disciplined capital deployment. The company trades at a notable discount to biopharma peers despite robust F...
Royalty Pharma plc ( RPRX ) Q3 2025 Earnings Call November 5, 2025 8:00 AM EST Company Participants George Grofik - Senior VP and Head of Investor Relations & Communications Pablo Legorreta - Founder,...